Clinical Trial Update: LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes [NA]

View source ↗

Summary

A clinical trial named LIGHT-MCI is investigating a combination of GLP-1 receptor agonist, SGLT2 inhibitor, and DPP-4 inhibitor for remission of mild cognitive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Type 2 Diabetes Mellitus

Drugs mentioned

• DPP-4 inhibitor
• GLP-1 receptor agonist
• SGLT2 inhibitor

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Type 2 Diabetes Mellitus, Mild Cognitive Impairment | NA | Status: ACTIVE_NOT_RECRUITING